Exicure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Exicure, Inc. on December 10, 2021. The filing addresses a material amendment to the company's credit agreement, a strategic realignment involving the wind-down of specific drug programs, significant management changes, and the results of an internal investigation into data integrity.
Key Financial Metrics and Debt
- Debt Reduction: The Company prepaid $10.0 million of its outstanding senior secured term loan debt with MidCap Financial Trust.
- Remaining Debt: The outstanding balance under the debt facility is now $7.5 million.
- Liquidity/Cash Control: The Company agreed to place $8.0 million (or a lesser agreed amount) into a blocked account governed by a control agreement by December 17, 2021.
- Restructuring Costs: The Company estimates total expenses of approximately $1.2 million related to the realignment plan, consisting entirely of cash expenditures for severance and termination costs.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for the period.
Material Changes and Strategic Realignment
The Company announced a plan to wind down its immuno-oncology program for cavrotolimod (AST-008) and its XCUR-FXN preclinical program for Friedreich's ataxia. Resources will be realigned to focus on:
- A preclinical program targeting SCN9A for neuropathic pain.
- Partnered programs with Ipsen Biopharm Limited (Huntington's disease and Angelman syndrome).
- A partnered program with AbbVie (hair loss disorders).
- Other undisclosed therapeutic candidates.
To support this shift, the Company will eliminate approximately 50% of its existing workforce on a staggered basis through January 2022. Implementation is expected to be complete by March 31, 2022.
Management Changes and Compensation
- CEO Appointment: Brian C. Bock (formerly CFO) was appointed Chief Executive Officer and Board member, effective December 10, 2021. His base salary was increased to $525,000 with a target bonus of 50%. He received a one-time retention award of $180,000.
- CTO Appointment and Departure: David Giljohann (former CEO) was appointed Chief Technology Officer and resigned from the Board. He will separate from the Company on January 30, 2022.
- CSO Appointment: Matthias Schroff (formerly COO) was appointed Chief Scientific Officer. He received a one-time retention award of $140,000, payable in two installments contingent on employment through May 31, 2022.
- CMO Departure: Douglas Feltner, Chief Medical Officer, is separating effective January 30, 2022, with a severance payment of approximately $200,000.
Risks, Contingencies, and Investigation Results
The Audit Committee completed an investigation into allegations of data improprieties by former Group Leader of Neuroscience, Dr. Grant Corbett, regarding the XCUR-FXN program. Key findings include:
- Dr. Corbett misreported raw data related to efficacy (not safety) in at least three experiments between autumn 2020 and February 2021.
- The misreported data was included in public presentations and SEC filings between January 7, 2021, and August 12, 2021.
- Dr. Corbett acted alone; management reasonably relied on his analysis without knowledge of the misconduct.
- The investigation concluded there was no material adverse impact on the Company's financial condition or results of operations, and no other programs were impacted.
The Board intends to enhance data management policies and procedures.
Investor Verification Checklist
- Verify the exact timing and amount of the $8.0 million blocked account deposit.
- Confirm the final headcount reduction and the specific timing of the 50% workforce elimination.
- Review the full text of Amendment No. 4 to the Credit Agreement for any covenants triggered by the blocked account or debt prepayment.
- Monitor future filings for the final severance costs associated with Dr. Giljohann's departure.
- Assess the impact of the XCUR-FXN data misreporting on the Company's intellectual property and regulatory standing, despite the "no material impact" conclusion.